Harpoon Therapeutics (HARP) Upgraded at Zacks Investment Research

Harpoon Therapeutics (NASDAQ:HARP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform, they are developing a pipeline of novel T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics Inc. is based in San Francisco, United States. “

HARP has been the topic of a number of other research reports. Wedbush initiated coverage on Harpoon Therapeutics in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $23.00 target price on the stock. Robert W. Baird initiated coverage on Harpoon Therapeutics in a research note on Monday, April 22nd. They issued an “outperform” rating and a $25.00 target price on the stock. Svb Leerink reaffirmed an “outperform” rating on shares of Harpoon Therapeutics in a research note on Tuesday, March 5th. Finally, Canaccord Genuity initiated coverage on Harpoon Therapeutics in a research note on Tuesday, March 5th. They issued a “buy” rating and a $24.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.00.

Shares of NASDAQ:HARP opened at $11.12 on Tuesday. The company has a market cap of $270.96 million and a PE ratio of -0.43. Harpoon Therapeutics has a 12 month low of $9.07 and a 12 month high of $17.85.

Harpoon Therapeutics (NASDAQ:HARP) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($8.15) EPS for the quarter. The firm had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.22 million. As a group, research analysts expect that Harpoon Therapeutics will post -2.78 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of HARP. MPM Asset Management LLC purchased a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $39,796,000. New Leaf Venture Partners L.L.C. purchased a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $21,262,000. Fosun International Ltd purchased a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $3,062,000. BlackRock Inc. purchased a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $879,000. Finally, Northern Trust Corp purchased a new stake in Harpoon Therapeutics in the 1st quarter valued at approximately $309,000. 0.19% of the stock is currently owned by hedge funds and other institutional investors.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Read More: Total Return

Get a free copy of the Zacks research report on Harpoon Therapeutics (HARP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.